We are international
Donate
TEXT SIZE   


Phase I VELCADE® Clinical Trials
05.01.08

US TRIALS

  • Safety Study of Dasatinib With Bortezomib for Multiple Myeloma (CA180-181)
    Orlando, FL

  • Phase I Study of Maintenance Bortezomib in Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant (WSU-D-2957)
    Detroit, MI - multicenter

  • Phase I Study of Sorafenib and Bortezomib in Patients With Advanced Malignancies (MAYO-MC0511)
    Rochester, MN

  • Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma (CLBH589B2207)
    Hackensack, NJ- multicenter

  • Phase I Study of Bortezomib and Flavopiridol in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms (MCV-MCC-6413)
    Richmond, VA - multicenter

  • Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Bortezomib in Patients With Advanced Multiple Myeloma (2005_018)
    multicenter

FOREIGN TRIALS

  • Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma (BRD/05/9-B)
    Nantes, France

  • Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma (CLBH589B2207)
    multicenter


 related articles